18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer

European Journal of Surgical Oncology

Volumn 30, Issue 1, 2004, Pages 15-19

  Zornoza, G ^a   Garcia Velloso M J ^a   Sola, J ^a   Regueira, F M ^a   Pina, L ^b   Beorlegui, C ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Clinica Universitaria   (Spain)

Author keywords

Axillary lymph nodes; Breast cancer; Positron emission tomography; Sentinel lymph node

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME; AXILLA; BREAST TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; LYMPH NODE; LYMPHADENECTOMY; MIDDLE AGED; PATHOLOGY; SCINTISCANNING;

ADULT; AGED; AXILLA; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0842323897     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2003.10.010     Document Type: Article

References (14)

1. Adams S, Baunm RP, Stuckensen T, Bitter K, Hor G. Prospective comparison of 18-F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998;25:1255-1260.
2. Venta LA. Evaluation of axillary node status with imaging modalities. Semm Breast Dis 1998;1:134-140.
3. Adler LP, Faulhaber PF, Schnur KC, Al-Kaisi NK, Shenk RR. Axillary lymph node metastases: screening with (F-18) 2-deoxy-D-fluoro-D-glucose (FDG) PET. Radiology 1997;203: 323-327.
4. Di Chiro G, De la Paz RL, Brooks RA et al. Glucose utilization of cerebral gliomas measured by (18) fluorodeoxyglucose and positron emission tomography. Neurology 1982;32: 1323-1329.
5. Kubota K, Matsuzwana T, Amemiya A et al. Imaging of breast cancer with (18-F) fluorodeoxyglucose and positron emission tomography. J Comp Assist Tomog 1989;13:1097-1098.
6. Avril N, Dose J, Janicke F et al. Metabolic characterization of breast tumours with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996;14:1848-1857.
7. Crippa F, Agresti R, Seregni E et al. Prospective evaluation of fluorine 18-FDG PET in presurgical stating of axilla in breast cancer. J Nucl Med 1998;39:4-8.
8. Schirmeister H, Kúhn T, Guhlmann A et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001;28:351-358.
9. Smith IC, Ogston KN, Whitford P et al. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fuorine-18)-fluoro-2-D-glucose. Ann Surg 1998;228:220-227.
10. Utech Ch, Young CS, Winter PF. Prospective evaluation of fluorine-18-fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunohistochemistry. Eur J Nucl Med 1996;23: 1588-1593.
11. Eubank WB, Mankoff DA. The role of PET in breast cancer: FDG and future directions. Semm Breast Dis 2002;5: 116-126.
12. Avril N, Dose J, Janickke F et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Nat Cancer Inst 1996;88: 1204-1209.
13. Trojani M, De Mascarel I, Bonichon F et al. Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and pronostic significance. Br J Cancer 1987;55:303-306.
14. Roston AY, Powe J, Kandil A et al. Positron emissión tomography in breast cancer: a clinicopathological correlation of results. Br J Radiol 1999;72:1064-1068.